Researchers at Mayo Clinic have identified an early survival response in ovarian cancer cells that may reduce the effectiveness of PARP inhibitors. The study shows that these cancer cells can rapidly activate protective mechanisms after treatment, and blocking this response could enhance the drugs’ therapeutic impact.

Arun Kanakkanthara and colleagues at Mayo Clinic found that ovarian cancer cells can rapidly activate a survival program shortly after exposure to PARP inhibitors, drugs commonly used to treat tumors with DNA repair defects. A key factor in this process is FRA1, a transcription factor that turns on genes helping cancer cells evade death.

Figure 1. Cancer Cells Resist PARP Inhibitors Quickly

The findings suggest that drug resistance can arise almost immediately, rather than gradually over time. By targeting this early survival response, existing therapies may become more effective and resistance could potentially be delayed or prevented. Figure 1 shows Cancer Cells Resist PARP Inhibitors Quickly.

Evaluating a Combination Treatment

The team tested whether Brigatinib could block ovarian cancer cells’ early survival response and enhance the effectiveness of PARP inhibitors. Brigatinib was chosen because it targets multiple signaling pathways that cancer cells use to survive.

The combination of brigatinib and a PARP inhibitor proved more effective than either drug alone, selectively targeting cancer cells while sparing normal cells. Researchers discovered that brigatinib works by inhibiting two signaling molecules, FAK and EPHA2, which aggressive ovarian cancer cells rely on for survival. Blocking both pathways simultaneously reduced the cells’ adaptive capacity, making them more sensitive to PARP inhibitors.

Identifying Optimal Candidates for Therapy

The study suggests a way to identify patients most likely to benefit from the combination therapy: tumors with higher levels of FAK and EPHA2 responded more strongly to the drug pairing. These molecules are also associated with more aggressive ovarian cancers, making this approach particularly promising for hard-to-treat cases.

John Weroha, senior author of the study, notes that targeting early resistance mechanisms could improve patient outcomes [1]. Overall, the findings provide new insight into how ovarian cancer evades treatment and highlight a potential strategy for enhancing therapy by disrupting early survival signals.

References:

1. https://scitechdaily.com/researchers-discover-surprising-new-ovarian-cancer-treatment-using-an-existing-drug/

Cite this article:

Janani R (2026), Researchers Identify New Ovarian Cancer Therapy, AnaTechMaz, pp. 707